Identifing Risk Factors for Pancreaticojejunostomy Leakage Following Pancreaticoduodenectomy

Sponsor
Dimitrios Vouros (Other)
Overall Status
Recruiting
CT.gov ID
NCT04798560
Collaborator
(none)
100
1
42.7
2.3

Study Details

Study Description

Brief Summary

Pancreatic cancer is an aggresive type of cancer with poor mean survival rates despite improvements in chemotherapy regimens and advances in surgical techniques. Surgery is the only therapeutic option with an intend to treat. Pancreaticoduodenectomy is indicated for malignancy in the pancreatic head as well as other periampullary tumors. One of the most fatal complications after Whipple operation is postoperative pancreatic fistula as a result of pancreatojejunostomy leakage. Various risk factors for pancreatojejunostomy leakage have been proposed, while there are others less studied.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pancreaticoduodenectomy

Detailed Description

This is a prospective observational study conducted in the 1st Propaedeutic Department of Surgery of the National and Kapodistrian University of Athens, Greece. Patients with imaging and/or histologically proven periampullary tumors in which Whipple operation is indicated will be enrolled in the study after signing a consent designed by the Hospitals Ethics Commitee and the Department of Surgery. Patients information and medical history will be recorded, giving emphasis on clinical presentation, signs and symptoms related to the patients disease. Laboratory tests will afterwards take place, including biochemical parameters such as total bilirubin levels, serum albumin, CA 19-9, CEA, HbA1c and ferritine levels prior to operation. During operation, as soon as the specimen has been removed, the horizontal and vertical dimension of the pancreatic cutting surface will be measured with the use of an one use sterile ruler and the area of the cutting surface will then be calculated as well as the ratio of the two dimensions (horizontal/vertical). The diameter of the pancreatic duct will be measured either with the same ruler in case diameter is equal or greater than 3mm or with a use of a plastic stent in case diameter is less than 3mm. Pancreatic texture will also be assesed. Other intraoperative datas will be recorded such as the anastomosis technique, duration of surgery, amount of fluid administration, transfusion with fresh frosen plasma or blood units.Postoperatively, amylase from the drains, white blood cell count, platelet count and serum crp levels will be recorded on the 1st, 3rd and 5th postoperative day in all patients. The definition used for postoperative pancreatic fistula (POPF) is based on the International Study Group of Pancreatic Fistula 2016 definition and patients will be categorised accordingly. There will be two arms of patients. The first arm will include patients with either no POPF or Biochemical Leak (BL) and the second arm patients with Grade B or C POPF.

Any complication in the early postoperative period ,defined as the first 30 days after Whipple operation, will be recorded and categorised according to Clavien Dindo classification, including reoperation, readmissions or prolongation of hospital stay. After discharge, follow up of the patients include the EORTC QLQ-C30 and EORTC QLQ-PAN 26 questionnaires that patients have to fill in one, three, six and twelve months after surgery. Reccurence and survival rates will accordingly be recorded.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Risk Factors for Pancreaticojejunostomy Leakage Following Whipple Operation
Actual Study Start Date :
Oct 10, 2018
Anticipated Primary Completion Date :
Apr 1, 2021
Anticipated Study Completion Date :
May 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Patients undergoing Whipple operation

After Whipple operation patients will be observed for complications and emphasis will be given on the presence of postoperative pancreatic fistula (POPF) according to the ISGPF 2016 definition. There will be to arms of patients. The first will include patients that do not develop POPF or either develop Biochemical Leak (Grade A). The second group consist of patients that develop either Grade B or Grade C POPF

Procedure: Pancreaticoduodenectomy
Patients udergo pancreaticoduodenectomy for periampullary tumors. All of them are observed for developing POPF

Outcome Measures

Primary Outcome Measures

  1. Development of Postoperative pancreatic fistula after pancreaticoduodenectomy [30 days]

    Following pancreaticoduodenectomy, patients are observed for developing POPF according to ISGPF definition

Secondary Outcome Measures

  1. Mortality [30 days]

    Mortality rates expressed in % of the patients

  2. Morbidity [30 days]

    Morbidity rates expressed in % of the patients

  3. Postoperative complications [30 days]

    Complications classified according to Clavien-Dindo Classification taking measures from I up to V

  4. Duration of Hospital stay [60 days]

    Duration of Hospital stay in days

  5. Readmission [30 days]

    Readmission rates expressed in % of the patients

  6. Reoperation [30 days]

    Reoperation rates expressed in % of the patients

  7. Overall survival [2 years]

    Estimation of days from operation until death expressed in days

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age more than or equal to 18 years

  2. periampullary pathologies (benign or malignant) with indication for panceaticoduodenectomy

  3. Pancreaticojejunal anastomosis performed

  4. Curative resection

  5. Signed informed consent form -

Exclusion Criteria:
  1. Age less than 18 years old

  2. One stage total pancreatectomy

  3. External wirsungostomy without pancreaticojejunal anastomosis

  4. Subtotal pancreatectomy without pancreaticojejunal anastomosis

  5. Left pancreatectomies

  6. Intraoperatively findings of unresectable tumors

  7. Pregnancy

  8. Concurrent participation in other study(ies)

Contacts and Locations

Locations

Site City State Country Postal Code
1 1st Propaedeutic Department of Surgery, Hippokrateion General Hospital Athens Attiki Greece 11527

Sponsors and Collaborators

  • Dimitrios Vouros

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dimitrios Vouros, Dr, University of Athens
ClinicalTrials.gov Identifier:
NCT04798560
Other Study ID Numbers:
  • 8515/31-05-2019
First Posted:
Mar 15, 2021
Last Update Posted:
Mar 15, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dimitrios Vouros, Dr, University of Athens
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 15, 2021